본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial

이용수 5

영문명
발행기관
대한신경정신의학회
저자명
Cheolmin Shin Young-Hoon Ko Se-Hoon Shim Ji Sun Kim Kyoung-Sae Na Sang-Woo Hahn Seung-Hwan Lee
간행물 정보
『Psychiatry Investigation』제17권 제8호, 796~803쪽, 전체 8쪽
주제분류
의약학 > 정신과학
파일형태
PDF
발행일자
2020.08.31
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Objective This study investigated the treatment response and cognitive enhancement effects of buspirone augmentation of escitalopram in patients with major depressive disorder (MDD), according to atypical feature subtypes of MDD. Methods An 8 week, randomized, parallel-controlled, open-label study was conducted. The Columbia Atypical Depression Diagnostic Scale was administered to evaluate atypical features. Patients were assigned randomly to the buspirone augmentation or non-buspirone groups. Symptom severity and cognitive function were evaluated using the 17-item Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Beck Depression Inventory, Beck Anxiety Inventory, digit span test, word fluency test, and Trail Making Tests A and B. Results A total of 89 patients were recruited. There were no significant differences in the measures between the groups; however, among the MDD patients without atypical features, the digit span and word fluency tests were improved by treatment. In the MDD patients without atypical features, the buspirone augmentation group showed a significant improvement on the digit span test compared to the non-buspirone group. Conclusion Buspirone augmentation did not demonstrate significant benefits in MDD patients; however, buspirone augmentation showed greater efficacy for the improvement of cognitive function in MDD patients without atypical features. Our study suggests that atypical features are an important factor for cognitive enhancement in buspirone augmentation treatment in patients with MDD.

목차

INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

Cheolmin Shin,Young-Hoon Ko,Se-Hoon Shim,Ji Sun Kim,Kyoung-Sae Na,Sang-Woo Hahn,Seung-Hwan Lee. (2020).Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial. Psychiatry Investigation, 17 (8), 796-803

MLA

Cheolmin Shin,Young-Hoon Ko,Se-Hoon Shim,Ji Sun Kim,Kyoung-Sae Na,Sang-Woo Hahn,Seung-Hwan Lee. "Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial." Psychiatry Investigation, 17.8(2020): 796-803

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제